Clinical Trials Logo

Colitis clinical trials

View clinical trials related to Colitis.

Filter by:

NCT ID: NCT03259334 Terminated - Ulcerative Colitis Clinical Trials

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

FIGARO UC 301
Start date: February 9, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of participant-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).

NCT ID: NCT03259308 Terminated - Ulcerative Colitis Clinical Trials

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

FIGARO UC 302
Start date: December 5, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of patient-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).

NCT ID: NCT03251118 Recruiting - Ulcerative Colitis Clinical Trials

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

TARGET-IBD
Start date: July 24, 2017
Phase:
Study type: Observational [Patient Registry]

TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

NCT ID: NCT03239704 Not yet recruiting - Ulcerative Colitis Clinical Trials

Improving Outcomes Among Urgent Care Clinic Patients With Inflammatory Bowel Disease

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

Inflammatory Bowel Diseases (IBD) refers to a category of disorders, consisting of Crohn's Disease (CD) and Ulcerative Colitis (UC), where segments of the gastrointestinal tract become inflamed and ulcerated. Canada has among the highest incidence rates of IBD in the world - 16.3 and 12.3 per 100,000 for CD and UC respectively. In the absence of a cure, the current goal of treatment is to manage patients in a milder state of remission. However, maintaining (or even achieving) remission is dependent on timely access to specialist IBD care; which in light of rising incidence rates have proven to be challenging. Moreover, patients often experience flare-ups of their gastrointestinal symptoms, while awaiting access to specialist care. In recent years, there has been increased integration of telemedicine services in gastroenterology practice. This change has been driven by a desire among IBD patients to have more flexible follow-up care, where 'virtual' care is provided as an adjunct to in-person consultations. Within the context of IBD, telemedicine might be effective in delivering routine and timely follow-up care to high-risk patients. The purpose of this study to determine whether telemedicine-based follow-up care can effectively manage the gastrointestinal symptoms of high-risk IBD patients and reduce their need for preventive health care services.

NCT ID: NCT03237260 Withdrawn - Ulcerative Colitis Clinical Trials

An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis

Start date: July 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to determine whether starting the drug vedolizumab earlier than its FDA approved use can lead to better control of UC then using older drugs that we have historically used to treat UC. Vedolizumab is FDA-approved to be used after initial Corticosteroid treatments have failed or other UC treatments have failed. We will study if using vedolizumab as an early treatment for your UC will allow you to get off corticosteroids and prevent UC from worsening and requiring surgery. Vedolizumab is given intravenously initially every 2 weeks and then every 8 weeks.

NCT ID: NCT03235752 Completed - Clinical trials for Active Ulcerative Colitis

Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis

Start date: February 6, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled phase II study.

NCT ID: NCT03232528 Completed - Ulcerative Colitis Clinical Trials

The Promotion Plan of Moxibustion on Ulcerate Colitis

Start date: November 1, 2016
Phase: N/A
Study type: Interventional

To evaluate the efficacy of Moxibustion in the treatment of Ulcerative Colitis, thus the scientific foundation for rational use of Moxibustion in clinical usage, in order to find admission of the Acupuncture and Moxibustion and even medicine field, accomplish popularization and application.

NCT ID: NCT03223012 Completed - Psoriasis Clinical Trials

Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service

IMPROVE
Start date: November 15, 2017
Phase:
Study type: Observational

This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.

NCT ID: NCT03221036 Recruiting - Clinical trials for Moderately to Severely Active Ulcerative Colitis

Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Start date: August 3, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the effect of vedolizumab intravenous IV as induction and maintenance treatment in Chinese participants with moderately to severely active ulcerative colitis (UC).

NCT ID: NCT03218202 Terminated - Ulcerative Colitis Clinical Trials

Stricture Definition and Treatment (STRIDENT) Observational Study.

STRIDENT
Start date: October 9, 2017
Phase:
Study type: Observational

Two thirds of patients with Crohn's disease require intestinal surgery at some time in their life. Intestinal strictures, that is narrowing of the bowel due to inflammation and scarring, are the most common reason for surgery. Despite the high frequency, associated disability, and cost there are no are no treatment strategies that aim to improve the outcome of this disease complication. The STRIDENT (stricture definition and treatment) studies aim to determine biochemical and imaging features associated with the development of strictures and in related STRIDENT studies develop strategies for treatment.